Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,949 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).
Kappert K, Böhm M, Schmieder R, Schumacher H, Teo K, Yusuf S, Sleight P, Unger T; ONTARGET/TRANSCEND Investigators. Kappert K, et al. Among authors: yusuf s. Circulation. 2012 Aug 21;126(8):934-41. doi: 10.1161/CIRCULATIONAHA.111.086660. Epub 2012 Jul 24. Circulation. 2012. PMID: 22829023 Clinical Trial.
Use of ramipril in preventing stroke: double blind randomised trial.
Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J; HOPE Investigators. Heart outcomes prevention evaluation. Bosch J, et al. Among authors: yusuf s. BMJ. 2002 Mar 23;324(7339):699-702. doi: 10.1136/bmj.324.7339.699. BMJ. 2002. PMID: 11909785 Free PMC article. Clinical Trial.
Effect of long-term therapy with ramipril in high-risk women.
Lonn E, Roccaforte R, Yi Q, Dagenais G, Sleight P, Bosch J, Suhan P, Micks M, Probstfield J, Bernstein V, Yusuf S; HOPE Investigators. Heart Outcomes Prevention Evaluation. Lonn E, et al. Among authors: yusuf s. J Am Coll Cardiol. 2002 Aug 21;40(4):693-702. doi: 10.1016/s0735-1097(02)02035-1. J Am Coll Cardiol. 2002. PMID: 12204499 Free article. Clinical Trial.
Who is fooling us?
Sleight P, Yusuf S. Sleight P, et al. Among authors: yusuf s. Lancet. 2002 Sep 14;360(9336):873-4. doi: 10.1016/S0140-6736(02)09974-9. Lancet. 2002. PMID: 12243941 No abstract available.
Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease.
Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, Teo K, Davis B, Montague P, Yusuf S; Study of Health Assessment and Risk in Ethnic Groups; Study of Health Assessment and Risk Evaluation in Aboriginal Peoples Investigators. Anand SS, et al. Among authors: yusuf s. Circulation. 2003 Jul 29;108(4):420-5. doi: 10.1161/01.CIR.0000080884.27358.49. Epub 2003 Jul 14. Circulation. 2003. PMID: 12860914
Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients.
Lonn E, Mathew J, Pogue J, Johnstone D, Danisa K, Bosch J, Baird M, Dagenais G, Sleight P, Yusuf S; Heart Outcomes Prevention Evaluation Study Investigators. Lonn E, et al. Among authors: yusuf s. Eur J Cardiovasc Prev Rehabil. 2003 Dec;10(6):420-8. doi: 10.1097/01.hjr.0000106836.97722.cf. Eur J Cardiovasc Prev Rehabil. 2003. PMID: 14671464 Clinical Trial.
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H; ONTARGET/TRANSCEND Investigators. Teo K, et al. Among authors: yusuf s. Am Heart J. 2004 Jul;148(1):52-61. doi: 10.1016/j.ahj.2004.03.020. Am Heart J. 2004. PMID: 15215792 Clinical Trial.
1,949 results